This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (92)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Patient Safety/ Medical Error  • Bioterrorism  • Alert me on articles by topic

Evidence for Safety and Efficacy Against Inhalational Anthrax

Arthur M. Friedlander, MD; Phillip R. Pittman, MD, MPH; Gerald W. Parker, DVM, PhD

JAMA. 1999;282:2104-2106.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Several countries are believed to have biological weapons programs capable of causing widespread devastating illness among unprotected individuals. Bacillus anthracis, the causative agent of anthrax, is one of the most likely pathogens to be used.¹ The decision by Secretary of Defense William S. Cohen to vaccinate the US Armed Forces against anthrax, using a licensed vaccine with which most civilian and military medical personnel were unfamiliar, prompts this review of the evidence of the safety and efficacy of the vaccine (anthrax vaccine adsorbed [AVA]).

The most common form of naturally occurring anthrax is cutaneous, acquired by direct inoculation of the organism through the skin after handling infected animal tissue or contaminated animal products. However, the form of the disease acquired as a result of a biological attack would likely be inhalational anthrax, caused by inhaling . . . [Full Text of this Article]

History of AVA

Safety of AVA

Efficacy of AVA in Humans and Animals

Efficacy Against Geographically Diverse Strains of B anthracis

Conclusion

Author Affiliations: US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Md.

RELATED ARTICLE

December 8, 1999
JAMA. 1999;282(22):2183-2184.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Birth Defects among Infants Born to Women Who Received Anthrax Vaccine in Pregnancy
Ryan et al.
Am J Epidemiol 2008;168:434-442.
ABSTRACT | FULL TEXT  

Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization
Cote et al.
Microbiology 2008;154:619-632.
ABSTRACT | FULL TEXT  

Responding to a Small-scale Bioterrorist Anthrax Attack: Cost-effectiveness Analysis Comparing Preattack Vaccination With Postattack Antibiotic Treatment and Vaccination
Schmitt et al.
Arch Intern Med 2007;167:655-662.
ABSTRACT | FULL TEXT  

Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax
Vietri et al.
Proc. Natl. Acad. Sci. USA 2006;103:7813-7816.
ABSTRACT | FULL TEXT  

Immunogenicity and Protective Efficacy of Bacillus anthracis Poly-{gamma}-D-glutamic Acid Capsule Covalently Coupled to a Protein Carrier Using a Novel Triazine-based Conjugation Strategy
Joyce et al.
J. Biol. Chem. 2006;281:4831-4843.
ABSTRACT | FULL TEXT  

Identification of a Protein Subset of the Anthrax Spore Immunome in Humans Immunized with the Anthrax Vaccine Adsorbed Preparation
Kudva et al.
Infect. Immun. 2005;73:5685-5696.
ABSTRACT | FULL TEXT  

Chimeric Influenza Virus Hemagglutinin Proteins Containing Large Domains of the Bacillus anthracis Protective Antigen: Protein Characterization, Incorporation into Infectious Influenza Viruses, and Antigenicity
Li et al.
J. Virol. 2005;79:10003-10012.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Defending against Bioterrorism: A Comparison of Vaccination and Antibiotic Prophylaxis against Anthrax
Fowler et al.
ANN INTERN MED 2005;142:601-610.
ABSTRACT | FULL TEXT  

Rabbit and Nonhuman Primate Models of Toxin-Targeting Human Anthrax Vaccines
Phipps et al.
Microbiol. Mol. Biol. Rev. 2004;68:617-629.
ABSTRACT | FULL TEXT  

Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins
Barth et al.
Microbiol. Mol. Biol. Rev. 2004;68:373-402.
ABSTRACT | FULL TEXT  

Inhalational Anthrax: Radiologic and Pathologic Findings in Two Cases
Wood et al.
Am. J. Roentgenol. 2003;181:1071-1078.
FULL TEXT  

Use of a Promoter Trap System in Bacillus anthracis and Bacillus subtilis for the Development of Recombinant Protective Antigen-Based Vaccines
Gat et al.
Infect. Immun. 2003;71:801-813.
ABSTRACT | FULL TEXT  

Neurological Aspects of Biological and Chemical Terrorism: A Review for Neurologists
Martin and Adams
Arch Neurol 2003;60:21-25.
ABSTRACT | FULL TEXT  

Search for Potential Vaccine Candidate Open Reading Frames in the Bacillus anthracis Virulence Plasmid pXO1: In Silico and In Vitro Screening
Ariel et al.
Infect. Immun. 2002;70:6817-6827.
ABSTRACT | FULL TEXT  

The Defense Medical Surveillance System and the Department of Defense Serum Repository: Glimpses of the Future of Public Health Surveillance
Rubertone and Brundage
Am. J. Public Health 2002;92:1900-1904.
ABSTRACT | FULL TEXT  

Early statistical detection of anthrax outbreaks by tracking over-the-counter medication sales
Goldenberg et al.
Proc. Natl. Acad. Sci. USA 2002;99:5237-5240.
ABSTRACT | FULL TEXT  

Mucosal or Parenteral Administration of Microsphere-Associated Bacillus anthracis Protective Antigen Protects against Anthrax Infection in Mice
Flick-Smith et al.
Infect. Immun. 2002;70:2022-2028.
ABSTRACT | FULL TEXT  

Relationship Between Prepregnancy Anthrax Vaccination and Pregnancy and Birth Outcomes Among US Army Women
Wiesen and Littell
JAMA 2002;287:1556-1560.
ABSTRACT | FULL TEXT  

Anthrax Spores Make an Essential Contribution to Vaccine Efficacy
Brossier et al.
Infect. Immun. 2002;70:661-664.
ABSTRACT | FULL TEXT  

Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax
Sellman et al.
Science 2001;292:695-697.
ABSTRACT | FULL TEXT  

Surveillance for Adverse Events Associated With Anthrax Vaccination--US Department of Defense, 1998-2000
JAMA 2000;283:2648-2649.
FULL TEXT